Citable filing context
HSIC's research view summarizes recent SEC filing context, starting with earnings from Aug 4, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 4, 2026 | earnings | Henry Schein reported Q2 2026 net sales of $3.5 billion and raised its full-year 2026 financial guidance. |
| Jul 30, 2026 | management_change | Henry Schein announced leadership transitions, with three executives moving to senior advisory roles effective October 30, 2026. |
| May 22, 2026 | management_change | William K. "Dan" Daniel was elected Independent Chairman of the Board, effective May 21, 2026. |
| Aug 4, 2026 | Guidance: adjusted_ebitda_growth | not reported to not reported |
| Aug 4, 2026 | Guidance: non_gaap_diluted_eps | 5.29 to 5.39 |
| Aug 4, 2026 | Guidance: total_sales_growth | 4.50 to 5.50 |
| Aug 4, 2026 | mda_quarterly | Henry Schein’s financial performance for the six months ended June 27, 2026, reflects steady growth, with net sales reaching $6.83 billion, a 6.5% increase over the prior-year period. This growth was driven by a 3.6% internal increase and 0.7% from acquisitions, bolstered by a 2.2% favorable foreign exchange impact. The Global Distribution and Value-Added Services segment remains the primary revenue driver, contributing $5.75 billion, while the Global Technology segment saw strong 8.0% internal growth, largely due to increased adoption of cloud-based practice management platforms. The company continues to execute its "2024 Plan," a restructuring initiative aimed at integrating acquisitions and improving operational efficiency, which incurred $41 million in charges during the first half of 2026. Management is navigating a complex macroeconomic environment, including ongoing tariff volatility and inflationary pressures. Liquidity remains stable, with $157 million in cash and significant access to credit, including a $1.0 billion revolving credit agreement and private placement facilities. Key risks identified include dependence on third-party suppliers, potential cybersecurity threats, and the integration challenges inherent in the company’s aggressive acquisition strategy. The leadership transition to CEO Frederick M. Lowery and the strategic partnership with KKR remain central to the company’s long-term BOLD+1 growth strategy. |
| May 5, 2026 | mda_quarterly | Net sales for the first quarter of 2026 increased 6.3% to $3.37 billion, driven by 2.5% internal growth, 0.7% from acquisitions, and a 3.1% foreign exchange tailwind. Growth was strongest in Global Specialty Products, which rose 8.1% due to value implants and biomaterials, and Global Technology, which grew 7.0% through the adoption of cloud-based practice management solutions. Global Distribution and Value-Added Services increased 6.1%, supported by U.S. dental equipment and practice transitions, though medical sales were tempered by lower respiratory diagnostic test volume. Net income remained stable at $112 million. Strategic developments include the appointment of Frederick M. Lowery as CEO in March 2026 and a $250 million strategic investment from KKR. The company is executing its BOLD+1 strategy via high-margin acquisitions and a restructuring plan slated for completion by 2027, which incurred $12 million in Q1 charges. Key risks include global trade volatility and tariffs, as well as the "One Big Beautiful Bill Act," which may reduce Medicaid funding and service utilization. Market trends favor the company's scale as the industry consolidates toward Dental Support Organizations (DSOs) and Group Purchasing Organizations (GPOs), while an aging population sustains long-term demand. |
Source: SEC EDGAR filing text and events; period Aug 4, 2026; filed Aug 4, 2026.
HSIC company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.